_______________________________________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___________)*
Calmare Therapeutics
________________________________________
(Name of Issuer)
Common Stock
________________________________________
(Title of Class of Securities)
204512107
________________________________________
(CUSIP Number)
December 31, 2017
________________________________________
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ x] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 204512107
________________________________________
-----------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Bard Associates, Inc. 36-3452497
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) / /
(b) / /
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Illinois
--------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares
Beneficially 500,000
Owned by ---------------------------------------------
Each Reporting 6. Shared Voting Power
Person with
0
---------------------------------------------
7. Sole Dispositive Power
2,500,025
---------------------------------------------
8. Shared Dispositive Power
0
---------------------------------------------
----------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
2,500,025
----------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) / /
-----------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
8.2%
-----------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
IA
-----------------------------------------------------------------------------
ITEM 1.
(a) Name of Issuer
Calmare Therapeutics
-----------------------------------------------------------------------------
(b) Address of Issuer's Principal Executive Offices
1375 Kings Highway East
Fairfield, CT 06824
------------------------------------------------------------------------------
ITEM 2.
(a) Name of Person Filing
Bard Associates, Inc.
-----------------------------------------------------------------------------
(b) Address of Principal Business Office or, if none, Residence
135 South LaSalle Street, Suite 3700
Chicago, IL 60603
-----------------------------------------------------------------------------
(c) Citizenship
United States
-----------------------------------------------------------------------------
(d) Title of Class of Securities
Common Stock
------------------------------------------------------------------------------
(e) CUSIP Number
204512107
------------------------------------------------------------------------------
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS
240.13d-1(b) or 240.13d-2(b) or (c), CHECK WHETHER THE
PERSON FILING IS A:
(a) / / Broker or dealer registered under section 15 of
The Act (15 U.S.C. 78o).
(b) / / Bank as defined in section 3(a)(6) of the Act
(15 U.S.C. 78c).
(c) / / Insurance company as defined in section 3(a)(19)
Of the Act (15. U.S.C. 78c).
(d) / / Investment company registered under section 8 of
The Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) / x / An investment adviser in accordance with Section
240.13d-1(b)(1)(ii)(E);
(f) / / An employee benefit plan or endowment fund in
accordance with Section 240.13d-1(b)(1)(ii)(F);
(g) / / A parent holding company or control person in
accordance with Section 240.13d-1(b)(1)(1)(ii)(G);
(h) / / A savings association as defined in Section 3(b) of
the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) / / A church plan that is excluded from the definition
of an Investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15. U.S.C. 80a-3);
(j) / / Group, in accordance with Section
240.13d-1(b)(1)(ii)(J).
-------------------------------------------------------
ITEM 4. OWNERSHIP
The amount of shares beneficially owned set forth in Item 4(a) is
comprised of 2,500,025 common shares held by Bard.
The information reported below in the Item 4 is as of December 31, 2017.
The percentage set forth in Item 4(b) is calculated based on the
30,376,639 shares of the Issuer's Common Stock outstanding as of
November 16,2017, as reported in the Issuer's Proxy Materials filed
January 12, 2018.
(a) Amount beneficially owned:
2,500,025
(b) Percent of Class
8.2%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
500,000
-----------------------------------------------------
(ii) Shared power to vote or to direct the vote
0
------------------------------------------------------
(iii) Sole power to dispose or to direct the disposition of
2,500,025
-------------------------------------------------------
(iv) Shared power to dispose or to direct the disposition of
0
---------------------------------------------------------
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date hereof
The reporting person has ceased to be the beneficial owner of more than five
Percent of the class of securities, check the following / /.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF
ANOTHER PERSON
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
WHICH ACQUIRED THE SECURITY BEING REPORTED ON
BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE
GROUP
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
ITEM 10.CERTIFICATION
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the
ordinary course of business and were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose
or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.
2/12/2018
--------------------------------------------
Date
/s/ Timothy B. Johnson
----------------------------------------------
Signature
Timothy B. Johnson/ President
-----------------------------------------------------
Name/Title